Disrupting the market and driving life-science innovation

Infusion 51a is an impact-focused investment fund changing the healthcare game

Disrupting the market and driving life-science innovation

Infusion 51a is an impact-focused investment fund changing the healthcare game

Don’t miss our first Demo Day in the UAE!

Coming soon

What is Infusion 51a?

Infusion 51a is an impact investment fund facilitating the development of innovative biotech solutions.

Our team has a wealth of experience in the biotech investment arena. We connect like-minded investors with successful entrepreneurs, both driven by a desire to make the world a better place.

We’re seeking inspiring leaders – passive observers need not apply!

What is Infusion 51a?

Infusion 51a is an impact investment fund facilitating the development of innovative biotech solutions.

Our team has a wealth of experience in the biotech investment arena. We connect like-minded investors with successful entrepreneurs, both driven by a desire to make the world a better place.

We’re seeking inspiring leaders – passive observers need not apply!

Looking to invest in something that turns the odds around?

We pursue visionary investors that have unwavering confidence in the technology of tomorrow. Once we connect with the right type of investor, our team ensures capital is allocated to quickly scale revolutionary life-science technologies. All businesses Infusion 51a work with have the potential to change the future of healthcare.

Looking to invest in something that turns the odds around?

We pursue visionary investors that have unwavering confidence in the technology of tomorrow. Once we connect with the right type of investor, our team ensures capital is allocated to quickly scale revolutionary life-science technologies. All businesses Infusion 51a work with have the potential to change the future of healthcare.

We have a people-first mindset

For us, being impact-driven goes beyond investing: our organization doesn’t just elevate life-science by sourcing capital. Instead, we pay particular attention to our ability to serve the community.

Together Against Glioblastoma is an Infusion 51a-led private Facebook Group that provides people with a platform where they can share experiences, receive guidance and find educational resources in their fight against the deadliest form of brain cancer.

Likewise, in August 2022 we launched in Dubai the #FacesNotNumbers campaign, aimed to shine a light on inspiring stories often hidden behind cancer statistics.

We have a
people-first mindset

For us, being impact-driven goes beyond investing: our organization doesn’t just elevate life-science by sourcing capital. Instead, we pay particular attention to our ability to serve the community.

Together Against Glioblastoma is an Infusion 51a-led private Facebook Group that provides people with a platform where they can share experiences, receive guidance and find educational resources in their fight against the deadliest form of brain cancer.

Likewise, in August 2022 we launched in Dubai the #FacesNotNumbers campaign, aimed to shine a light on inspiring stories often hidden behind cancer statistics.

A look into the biotech landscape

$ 793.8 B
Global Biotechnology market size in 2021 (USD)
$ 1.6 T
Estimated Global Biotech market size in 2030 (USD)
8.7 %
Expected Compound Annual Growth Rate (CARG)
$ 2 T
combined value of biotech companies (a 5.4x increase since 2016)
84
healthtech and biotech unicorns were created in 2021 alone

The size and variety of the biotech sector make it suitable for almost anyone to build a diversified portfolio. Over the past decade, investors have repeatedly profited from biotech’s limitless potential, with stocks having far outperformed the S&P 500 (Mckinsey, 2022). It‘s never too late to start — why not doing it now?

Biotechnology Global Industry Analysis and Forecast 2022 – 2030 (Precedence Research)

Biotech and Precision Medicine evolution timeline 

Biotechnology has rapidly improved and changed the landscape of treatment options, with precision medicines using big data, proteomics, transcriptomic, and molecular imaging to create new systemic therapies. These advancements translate into countless opportunities for investors and, ultimately, better outcomes for patients. 

2010
First Clinical Interpretation
of Human Genome
.
.
.
2013
First FDA authorization for
next-generation sequencer
.
.
.
2015
“All of Us.” US government
announces a precision
medicine national initiative
.
.
2016
Genetic testing
popularization
.
.
.
2017
AHA Precision Medicine
Platform was launched,
offering cloud computing, diverse datasets, and
data harmonization
2018
Increasing popularity of
precision medicine
research with nearly 30
thousand written
worldwide
2019
Proliferation of artificial
intelligence to enhance the
practice of laboratory
medicine
.
2020
COVID-19 pandemic
challenged healthcare
professionals to change
toward more personalized
approaches
2021
Hyper-individualized
treatments
.
.
.

Sources: Surgical Oncology Clinics of North America (2021), The Lancet (2021), Frontiers in Genetics (2020), BMC Medical Informatics and Decision Making (2018), International Risk Governance Council (2018)

Sources: Surgical Oncology Clinics of North America (2021), The Lancet (2021), Frontiers in Genetics (2020), BMC Medical Informatics and Decision Making (2018), International Risk Governance Council (2018)

Get your Easy Investors Guide

Get your Easy Investors Guide